Cargando…
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of anti-PD-1 and oncolytic measles vaccine in an i...
Autores principales: | Veinalde, Rūta, Pidelaserra-Martí, Gemma, Moulin, Coline, Tan, Chin Leng, Schäfer, Theresa E., Kang, Na, Ball, Claudia R., Leichsenring, Jonas, Stenzinger, Albrecht, Kaderali, Lars, Jäger, Dirk, Ungerechts, Guy, Engeland, Christine E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886093/ https://www.ncbi.nlm.nih.gov/pubmed/36726983 http://dx.doi.org/10.3389/fimmu.2022.1096162 |
Ejemplares similares
-
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
por: Veinalde, Rūta, et al.
Publicado: (2021) -
Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity
por: Wu, Ying, et al.
Publicado: (2022) -
Immunotherapy: Reshape the Tumor Immune Microenvironment
por: LV, Bingzhe, et al.
Publicado: (2022) -
Single-cell transcriptomics of peripheral blood reveals anti-tumor systemic immunity induced by oncolytic virotherapy
por: Wu, Quanyou, et al.
Publicado: (2022) -
Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists
por: Backhaus, Paul S., et al.
Publicado: (2019)